SCHEMBL10024088

SCHEMBL10024088

CCC1OC(n2cc(Br)c(N)nc2=O)C([18F])C1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADK P55263 3/20 0.48
PRMT5 O14744 9/20 0.41
METTL3 Q86U44 7/20 0.41
PDE2A O00408 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
ADRA1A P35348 1/20 0.40
PDE4D Q08499 1/20 0.40
PDE3A Q14432 1/20 0.40
LMNA P02545 2/20 0.38
MTOR P42345 2/20 0.38
THRB P10828 1/20 0.38
MDM2 Q00987 1/20 0.38
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
GMNN O75496 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
NFKB1 P19838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13908141 0.89 PDE2A (0.50) PDE2AADORA3ADORA2AADORA1ADRA1A
SCHEMBL6722530 0.89 PDE2A (0.50) PDE2AADORA3ADORA2AADORA1ADRA1A
SCHEMBL6722527 0.89 PDE2A (0.50) PDE2AADORA3ADORA2AADORA1ADRA1A
SCHEMBL720256 0.89 PDE2A (0.50) PDE2AADORA3ADORA2AADORA1ADRA1A
SCHEMBL369266 0.89 PDE2A (0.50) PDE2AADORA3ADORA2AADORA1ADRA1A
SCHEMBL10024087 0.87 PDE2A (0.45) ADKPRMT5METTL3PDE2AADORA3
SCHEMBL10024086 0.87 ALB (0.46) ADKPRMT5PDE2AADORA3ADORA2A
SCHEMBL10024109 0.87 PDE2A (0.45) ADKPRMT5METTL3PDE2AADORA3
SCHEMBL10024073 0.87 PDE2A (0.40) ADKPRMT5METTL3PDE2AADORA3
SCHEMBL10885781 0.79 PDE2A (0.49) PDE2AADORA3ADORA2AADORA1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101740-B2 Positron emission tomography probes for imaging immune activation and selected cancers THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-01-24 US disclosed
US-20090105184-A1 POSITRON EMISSION TOMOGRAPHY PROBES FOR IMAGING IMMUNE ACTIVATION AND SELECTED CANCERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105184-A1 POSITRON EMISSION TOMOGRAPHY PROBES FOR IMAGING IMMUNE ACTIVATION AND SELECTED CANCERS PAICS, ADA, DCTD ADK 137/4885PRMT5 2659/4885METTL3 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.